**Core Concept:** Acute Promyelocytic Leukemia (APL) is a subtype of Acute Myeloid Leukemia (AML) characterized by the genetic mutation involving the PML-RARA fusion gene. This fusion gene disrupts normal hematopoiesis, leading to abnormal blood cell production and increased susceptibility to bleeding due to impaired platelet function and decreased hemoglobin levels.

**Why the Correct Answer is Right:** The correct answer, **D**, refers to the key pathophysiological process in APL. The PML-RARA fusion gene leads to impaired platelet function and decreased hemoglobin levels, ultimately causing the severe hemorrhage seen in APL patients.

**Why Each Wrong Option is Incorrect:**

A. **Option A:** Hemostasis involves a complex interplay between platelets, coagulation factors, and vessel walls. While bleeding in APL is a result of impaired platelet function, the coagulation cascade is usually intact.

B. **Option B:** Hemostasis is primarily disturbed in APL due to platelet dysfunction, not a deficiency in clotting factors. While clotting factors may be mildly affected in some cases, they are not the primary cause of bleeding.

C. **Option C:** The primary cause of bleeding in APL is impaired platelet function resulting from the PML-RARA fusion gene, rather than a decrease in white blood cells.

**Clinical Pearl:** The presence of PML-RARA fusion gene and severe hemorrhage in APL serve as key diagnostic criteria for this disease subtype. Early recognition and treatment are essential to improve survival rates, which include the use of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy.